Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
08:02am, Saturday, 30'th May 2026
Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of disease progression, relapse or dea
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.
Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report?
12:31pm, Thursday, 28'th May 2026
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Here's Why Incyte (INCY) is a Strong Momentum Stock
10:51am, Tuesday, 26'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
09:00am, Tuesday, 26'th May 2026
Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. E
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out
12:02pm, Monday, 25'th May 2026
Incyte NASDAQ: INCY Chief Medical Officer Steven Stein outlined the company's development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989
Here's Why Incyte (INCY) is a Strong Value Stock
10:41am, Friday, 22'nd May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Incyte (INCY) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 21'st May 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Inside Incyte's $120 Million AI For Drug Development Deal
12:10pm, Wednesday, 20'th May 2026
In this week's edition of InnovationRx, we look at a new AI drug development deal, a pill for sleep apnea, Commure's $7 billion valuation, and more. To get it in your inbox, subscribe here.
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
09:00am, Wednesday, 20'th May 2026
[url="]Incyte[/url] (Nasdaq:INCY) and [url="]Genesis Molecular AI[/url] today announced a significant expansion of their strategic collaboration building and d
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
08:00am, Wednesday, 20'th May 2026
WILMINGTON, Del. & SAN MATEO, Calif.--(BUSINESS WIRE)--Incyte and Genesis expand molecular AI collaboration to accelerate
drug discovery.
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
01:40pm, Tuesday, 19'th May 2026
Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
08:00am, Tuesday, 19'th May 2026
WILMINGTON, Del. & SAN FRANCISCO--(BUSINESS WIRE)---- $INCY--Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development.
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build
01:10am, Monday, 18'th May 2026
Incyte NASDAQ: INCY President and CEO Bill Meury said the company's post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business
